{"text": "These favorable effects on cardiovascular events were offset by an increased rate of serious bleeding ( 1.4 % , vs. 0.9 % in the clopidogrel group ) and fatal bleeding ( 0.4 % vs. 0.1 % ) .", "label": "", "metadata": {}, "score": "31.891113"}
{"text": "The primary study endpoint was the occurrence of combined safety endpoint ( CSEP ) ; secondary endpoints included major vascular complications and life - threatening bleeding .", "label": "", "metadata": {}, "score": "33.151207"}
{"text": "Based on subgroup analysis , the sooner the drug is given , greater the benefit .Bleeding - related death was also reduced ( 4.9 % vs. 5.7 % , respectively ) .", "label": "", "metadata": {}, "score": "33.350544"}
{"text": "The association between this secondary outcome and MPV is weaker compared to the association with the other outcomes studied ; this is probably secondary to the low number of life - threatening bleeding events in our patient cohort .", "label": "", "metadata": {}, "score": "34.309452"}
{"text": "Exact data on timing from injury to treatment and certainty that bleeding was the cause of death may not be accurate .However , in the setting of a large placebo - controlled randomized clinical trial it is expected that baseline differences ( measured and unmeasured ) confounders are well - balanced between study groups .", "label": "", "metadata": {}, "score": "37.134552"}
{"text": "The two studies of the CRAS-2 suggest the drug should be administered in low - doses and routinely in the management of bleeding trauma patients , but only in the first 3 hours after the trauma .", "label": "", "metadata": {}, "score": "38.248573"}
{"text": "Number of hospitalizations and ER visits for other cardiovascular events not included in the primary composite endpoint .the primary ( composite ) endpoint and the individual components of the primary end point in subjects who are CYP2C19 intermediate metabolizers ( IM ) with clopidogrel EM and prasugrel populations .", "label": "", "metadata": {}, "score": "39.177185"}
{"text": "The primary endpoint of the study was the proportion of patients who reached hematocrit control without phlebotomy and a greater than 35 % reduction in spleen volume .", "label": "", "metadata": {}, "score": "39.359814"}
{"text": "However , recent research suggests that in vitro anti - platelet response to clopidogrel may be limited or lost in up to 30 % of treated individuals , and may be associated with inferior clinical outcomes .", "label": "", "metadata": {}, "score": "39.67955"}
{"text": "To evaluate response duration , time to IPSS progression , and loss of RBC transfusion independence in these patients .To evaluate hospitalization duration , rates of rehospitalization for non - hematological toxicities , severe bleeding or febrile neutropenia .", "label": "", "metadata": {}, "score": "39.710037"}
{"text": "Incidence of hospitalization for site- and cause - specific bleeding [ Time Frame : 6 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "39.797283"}
{"text": "These data justify expanding the entry criteria for the GeCCO study to include patients with a recent prescription for clopidogrel or prasugrel but without a precipitating ACS event .", "label": "", "metadata": {}, "score": "40.441856"}
{"text": "Also , dual antiplatelet administration , warfarin utilization , baseline haemoglobin levels , and baseline platelet count levels were not found to be independent predictors of the outcomes studied .", "label": "", "metadata": {}, "score": "40.63586"}
{"text": "A genetic substudy subsequently published by Mega , et al . examined the association between CYP2C19 genotypes and cardiovascular outcome in a subset of 1,477 clopidogrel - treated subjects enrolled in the TRITON - TIMI 38 study .", "label": "", "metadata": {}, "score": "41.044594"}
{"text": "The reduction of gastric erosions through Week 12 was dose dependent , with 36 mcg and 54 mcg demonstrating statistical significance .The time - to - onset of all ulcer or erosion development was delayed in the cobiprostone cohorts with overall statistical significance across the 12 week treatment period .", "label": "", "metadata": {}, "score": "41.662403"}
{"text": "Incidence of hospitalization for site- and cause - specific bleeding [ Time Frame : 6 and 12 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "41.94129"}
{"text": "Primary endpoint : .To confirm safety and hematological toxicity in 14 additional patients .Secondary endpoints .To evaluate response duration , time to IPSS progression , and loss of RBC transfusion independence in these patients .", "label": "", "metadata": {}, "score": "42.35268"}
{"text": "A series of recent articles have explored the effect of genetic polymorphisms in CYP2C19 on the anti - platelet activity of clopidogrel as well as clinical outcomes following PCI .", "label": "", "metadata": {}, "score": "42.471676"}
{"text": "The primary safety endpoint was major bleeding during the treatment period .In the study , the incidence in major bleeding for both Eliquis doses was not statistically different from placebo .", "label": "", "metadata": {}, "score": "42.58541"}
{"text": "Only at the end of the study period TXA was given as part of a bleeding protocol .During the pre - protocol phase indications and doses of TXA were determined by the attending physicians , which make it a challenge to interpret the results .", "label": "", "metadata": {}, "score": "42.734604"}
{"text": "The primary endpoint of the trial was the percentage change in triglyceride level from baseline to week 12 , and the secondary endpoint was the reduction in non - HDL - cholesterol .", "label": "", "metadata": {}, "score": "43.269447"}
{"text": "In a meta - analysis of 16 studies including 3,519 patients , life - threatening bleeding occurred in 15.6 % ( 95 % CI : 11.7 % to 20.7 % ) while major vascular complications occurred in 11.9 % ( 95 % CI : 8.6 % to 16.4 % ) [", "label": "", "metadata": {}, "score": "43.62853"}
{"text": "Fatal or non - fatal vascular occlusive events were similar in both groups .Strengths . \u00b7Largest placebo - controlled randomized clinical trial in transfusion in trauma to date , including 20.211 patients from 40 countries ; . \u00b7", "label": "", "metadata": {}, "score": "43.87019"}
{"text": "Life - threatening bleeding ( seen in 67 patients , i.e. , 20.3 % ) and major vascular complications ( seen in 49 patients , i.e. , 14.8 % ) contributed mainly to CSEP .", "label": "", "metadata": {}, "score": "43.90476"}
{"text": "The risk also appears to be increased by traumatic or repeated epidural or spinal puncture .Monitor patients for signs and symptoms of neurologic impairment .", "label": "", "metadata": {}, "score": "44.23935"}
{"text": "To assess the non - inferiority of clopidogrel therapy in those subjects who are CYP2C19 extensive metabolizers compared to prasugrel therapy on the composite primary end point of cardiovascular death , nonfatal MI , or nonfatal stroke .", "label": "", "metadata": {}, "score": "44.330246"}
{"text": "The primary safety endpoint was major bleeding .The adjudicated major bleeding and clinically relevant non - major ( CRNM ) bleeding at any anatomical site were generally lower in the Eliquis group as compared to the enoxaparin / warfarin group .", "label": "", "metadata": {}, "score": "44.41239"}
{"text": "The risk of death , non - fatal MI or cardiovascular stroke at 1 year after PCI was 3.58 times greater in patients carrying two loss - of - function alleles compared to wild - type patients .", "label": "", "metadata": {}, "score": "44.529022"}
{"text": "Its subgroup analysis ; and . \u00b7The MATTERs trial , a fairly large retrospective study in combat injury including 896 patients ; . \u00b7A Cochrane systematic review of the literature published in 2011 , on the use of anti fibrinolytic for the treatement of traumatized patients that are bleeding 9 .", "label": "", "metadata": {}, "score": "45.317303"}
{"text": "Efficacy across subgroups , including age , gender , body mass index ( BMI ) , renal function , extent of index PE , location of DVT thrombus , and prior parenteral heparin use was generally consistent .", "label": "", "metadata": {}, "score": "45.513306"}
{"text": "In the AMPLIFY trial , Eliquis was shown to be non - inferior for the treatment of recurrent venous thromboembolism ( VTE)/VTE - related death and was statistically superior in the primary safety endpoint of major bleeding vs. enoxaparin / warfarin .", "label": "", "metadata": {}, "score": "45.537193"}
{"text": "The unadjusted analysis for the massive transfusion group showed an absolute reduction of 13.7 % ( relative reduction of 49 % ) with the use of TXA .", "label": "", "metadata": {}, "score": "45.85704"}
{"text": "Authors tried to address confounders and baseline differences between groups performing an adjusted analysis ( multivariate logistic regression ) ; included parameters that had pd\"0.15 in their univariate analysis of mortality in both overall and massively transfused cohorts ; . \u00b7", "label": "", "metadata": {}, "score": "46.25849"}
{"text": "If , as is the case here , the population receiving these drugs includes significant numbers of patients either without recent hospitalization for ACS and/or with stable coronary disease , then the population of the GeCCO study may justifiably be expanded to include these new indications .", "label": "", "metadata": {}, "score": "46.306892"}
{"text": "The results demonstrated lower proportions of hypocoagulable patients receiving TXA in either the overall cohort or the massive transfusion subgroups on admission to the Intensive Care Unit ; . \u00b7 Effect size might be even higher due to selection bias against showing favorable outcome for the TXA group .", "label": "", "metadata": {}, "score": "46.39599"}
{"text": "Thus , valve embolization occurred in 11 patients ( 3.3 % ) while valve recapturing was performed in 7 patients ( 2.1 % ) .A second valve was necessary in 12 patients ( 3.6 % ) .", "label": "", "metadata": {}, "score": "46.57187"}
{"text": "View at Google Scholar .B. van Der Loo and J. F. Martin , \" A role for changes in platelet production in the cause of acute coronary syndromes , \" Arteriosclerosis , Thrombosis , and Vascular Biology , vol .", "label": "", "metadata": {}, "score": "46.671455"}
{"text": "This study is a multicenter , randomized , open - label active controlled study .Three thousand women undergoing urgent or elective PCI from at least 50 centers will be randomized to either transradial or transfemoral PCI .", "label": "", "metadata": {}, "score": "46.882347"}
{"text": "Khatri et al . have recently performed a meta - analysis comprising 49 studies which enrolled 16,063 patients and showed that vascular complications are a significant complication of transarterial procedures compared with transapical procedures ( 14.2 % versus 3.4 % ; . )", "label": "", "metadata": {}, "score": "47.582237"}
{"text": "Thus , it is conceivable that the drop in mortality may have been caused by other effects of this drug , including its known anti - inflammatory properties due to plasmin inhibition 6 . \u00b7", "label": "", "metadata": {}, "score": "47.632996"}
{"text": "The antithrombotic regimen was noted for each patient .Furthermore , in all cases , blood samples were drawn in a standard fashion in the fasting overnight state and sent to the laboratory for analysis ; blood samples were taken at admission before starting any medication and before performing any intervention .", "label": "", "metadata": {}, "score": "48.011765"}
{"text": "Primary Efficacy Endpoint : Composite of BARC Types 2 , 3 , and 5 bleeding or vascular complications .[ Time Frame : From first arterial access post - randomization to 72 hours or hospital discharge , whichever occurs first . ]", "label": "", "metadata": {}, "score": "48.209114"}
{"text": "The significant predictors of the outcomes are reported in Table 2 .MPV was shown to be a predictor of both the primary and secondary endpoints .", "label": "", "metadata": {}, "score": "48.31433"}
{"text": "To compare the incidence of individual components of the primary end point .[ Time Frame : 6 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "48.342674"}
{"text": "To compare the incidence of the composite primary endpoint between the two study groups .[ Time Frame : 12 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "48.364937"}
{"text": "Under - reporting might also account for the low frequency of events ; . \u00b7A wide spectrum of severity of injury might be present due to the very pragmatic inclusion criteria , which makes difficult to determine the group of patients that would benefit the most from using TXA ; only 50 % of the entire cohort received a transfusion .", "label": "", "metadata": {}, "score": "48.615555"}
{"text": "Results of a prospective , randomized , open - label phase 3 study of ruxolitinib in polycythemia vera patients resistant to or intolerant of hydroxyurea : the RESPONSE trial .", "label": "", "metadata": {}, "score": "48.745502"}
{"text": "To determine the response rate as defined by the 2006 modified IWG criteria .Previous biological and or targeted therapies of MDS or AML are allowed if stopped more than 1 month before inclusion .", "label": "", "metadata": {}, "score": "48.8908"}
{"text": "Large retrospective cohort ( 896 consecutive admissions ) involving combat patients that received any blood transfusion ; it is assumed that bleeding patients are most likely to benefit from the intervention ; . \u00b7", "label": "", "metadata": {}, "score": "49.455223"}
{"text": "Patients receiving clopidogrel 75 mg / day as prescribed by their physician , and are extensive metabolizers by CYP2C19 genotype .Prasugrel .Patients receiving prasugrel 5 or 10 mg / day as prescribed by their physician The hypothesis of the SAFE - PCI for women trial is that , compared with transfemoral PCI , transradial PCI will result in a significant reduction in bleeding and vascular complications .", "label": "", "metadata": {}, "score": "49.56228"}
{"text": "Life - threatening bleeding and major vascular complications were the two major contributing factors to CSEP .Significant predictors of CSEP were MPV and logistic Euroscore .", "label": "", "metadata": {}, "score": "49.62673"}
{"text": "With regard to major vascular complications , female sex , previous MI , RDW , and MPV were shown to be significant determinants in multivariate analysis while PAD , RDW , and MPV were shown to be independent predictors of life - threatening bleeding .", "label": "", "metadata": {}, "score": "49.783768"}
{"text": "Therefore , CRASH-2 collaborators performed an exploratory post - hoc analysis of the effect of TXA on mortality due to bleeding .Question .Main Findings of this Study .", "label": "", "metadata": {}, "score": "50.19136"}
{"text": "Question .What is the effect of TXA on measures of coagulopathy and survival following wartime injury ?Main Findings of this Study .In the overall cohort ( patients receiving any blood transfusion within 24 hours of hospitalization ) , a 6.5 % absolute reduction in in - hospital mortality was observed in the TXA group .", "label": "", "metadata": {}, "score": "50.21405"}
{"text": "Current Primary Outcome Measures ICMJE ( submitted : April 4 , 2012 ) .Non - inferiority of clopidogrel therapy in CYP2C19 extensive metabolizers with cardiovascular disease [ Time Frame : 6 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "50.390038"}
{"text": "The subjects were randomized to first receive an intravenous ( i.v . ) infusion of esomeprazole 80 mg over 30 minutes followed by 8 mg i.v./hour for 72 hours , and then receive 40 mg oral treatment for 27 days .", "label": "", "metadata": {}, "score": "50.75481"}
{"text": "24 , pp .3006 - 3008 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. K. Kodali , M. R. Williams , C. R. Smith et al . , \" Two - year outcomes after transcatheter or surgical aortic - valve replacement , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "50.91033"}
{"text": "The risk of these events is increased by the use of postoperative indwelling epidural catheters or by the concomitant use of drugs affecting hemostasis .Patients should be frequently monitored for signs and symptoms of neurological impairment .", "label": "", "metadata": {}, "score": "50.91491"}
{"text": "Subgroup variables were specified a priori in the original research protocol and measured at baseline ; . \u00b7The hypothesis of TXA reducing early deaths due to bleeding was specified a priori . \u00b7", "label": "", "metadata": {}, "score": "50.985294"}
{"text": "Life - threatening bleeding and major vascular events were adjudicated independently by 2 cardiologists and one cardiac surgeon .All patients provided written informed consent for the procedure and data collection .", "label": "", "metadata": {}, "score": "51.31917"}
{"text": "[ Time Frame : 6 months ] [ Designated as safety issue : No ] .Total health care resource utilization and cost - effectiveness [ Time Frame : 6 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "51.39679"}
{"text": "The patient must have recovered from all acute toxicities from any previous therapy .Choosing to participate in a study is an important personal decision .", "label": "", "metadata": {}, "score": "51.445084"}
{"text": "The TXA group received more red blood cell , plasma , platelet and cryoprecipitate transfusions than the placebo group ; . \u00b7Approximately half of the patients included in the study did not have coagulation data available for analysis ; . \u00b7", "label": "", "metadata": {}, "score": "51.547844"}
{"text": "Further studies of larger patient populations are required to confirm our results , especially the cutoff point for MPV of 10.75 fL identified using ROC analysis .", "label": "", "metadata": {}, "score": "51.68618"}
{"text": "Furthermore , we managed to adjust for multiple potential confounders that could influence the combined safety endpoint including sheath size and antiplatelet therapy at baseline .", "label": "", "metadata": {}, "score": "51.88399"}
{"text": "The blinded , randomized , multicenter studies enrolled 1,049 patients with previous cerebrovascular disease , who were prescribed daily aspirin ( 325 mg ) for at least three months for secondary prevention of cardiovascular events .", "label": "", "metadata": {}, "score": "51.94319"}
{"text": "A total of approximately 3000 women will be randomized to obtain a cohort of approximately 1800 patients undergoing PCI .Based on this statistical futility , the DSMB has recommended stopping enrollment .", "label": "", "metadata": {}, "score": "51.99187"}
{"text": "171 - 175 , 2013 .View at Google Scholar .C. Bernelli , A. Chieffo , M. Montorfano et al . , \" Bleeding events after transcatheter aortic valve implantation : usefulness of baseline activated clotting time in guiding the antithrombotic regimen during transcatheter aortic valve implantation procedures , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "52.15065"}
{"text": "A Phase I / II Multicenter Study of IV Clofarabine in Patients With High - Risk Myelodysplastic Syndrome Who Have Failed Therapy With Azacitidine : the NIDEVOL Study .", "label": "", "metadata": {}, "score": "52.6745"}
{"text": "Adjusted analysis showed that the subgroup effect is independent of pre - specified baseline prognostic factors and other non - significant interactions ; . \u00b7The TXA reduction in bleeding - related mortality was consistent with the reduction observed in all - cause deaths , which supports the hypothesis of tranexamic acid preventing bleeding and improving survival in trauma .", "label": "", "metadata": {}, "score": "53.055405"}
{"text": "Bleeding can occur at any site during LOVENOX(R ) therapy .An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site .", "label": "", "metadata": {}, "score": "53.07173"}
{"text": "A low baseline MPV was shown for the first time to be a significant predictor of CSEP , major vascular complications , and life - threatening bleeding following TF - TAVI .", "label": "", "metadata": {}, "score": "53.12586"}
{"text": "Bleeding trauma patients may develop a complex and unique coagulopathy ; where multiple mechanistic factors such as dilution , consumption , acidosis , hypothermia , poor fibrinogen utilization , and excessive clot breakdown ( hyperfibrinolysis ) are responsible for its development 2 .", "label": "", "metadata": {}, "score": "53.201977"}
{"text": "Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study .Brief Summary .The primary objective of this trial is to demonstrate the non - inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited to the estimated 70 % of the population that are CYP2C19 extensive metabolizers .", "label": "", "metadata": {}, "score": "53.20604"}
{"text": "April 4 , 2011 .Pozen issued results from the phase I trial of PA32540 , a tablet for the secondary prevention of cardiovascular disease in patients at risk for aspirin - associated gastric ulcers .", "label": "", "metadata": {}, "score": "53.320637"}
{"text": "In Press 2011 .[Links ] .Roberts I , Shakur H , Ker K , Coats T , CRASH-2 trial collaborators .Antifibrinolytic therapy for acute traumatic injury .", "label": "", "metadata": {}, "score": "53.39265"}
{"text": "CRASH-2 Trial Collaborators : The Importance of early treatment with tranexamic acid in bleeding trauma patients : an exploratory analysis of the CRASH-2 randomized controlled trial .", "label": "", "metadata": {}, "score": "53.503033"}
{"text": "( 2 ) A cutoff point for MPV of 10.75fL is identified .Above this value a lower incidence of vascular and bleeding complications is observed , resulting in lower CSEP .", "label": "", "metadata": {}, "score": "53.540985"}
{"text": "[Links ] .Martin K , Wiesner G , Breuer T , Lange R , Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery : a one - year follow - up of 1188 consecutive patients .", "label": "", "metadata": {}, "score": "53.877865"}
{"text": "Predictors of vascular complications were female sex , previous myocardial infarction , red blood cell distribution width ( RDW ) , and MPV while predictors of life - threatening bleeding were peripheral arterial disease , RDW , and MPV .", "label": "", "metadata": {}, "score": "53.932713"}
{"text": "Unfortunately , the in - trial response to clopidogrel among the genetic substudy participants differed from that of the overall clopidogrel study cohort , thus preventing direct comparisons of clopidogrel to prasugrel as a function of CYP2C19 genotype .", "label": "", "metadata": {}, "score": "54.212273"}
{"text": "1225 - 1228 , 2009 .View at Google Scholar .M. C. Berndt , Y. Shen , S. M. Dopheide , E. E. Gardiner , and R. K. Andrews , \" The vascular biology of the glycoprotein Ib - IX - V complex , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "54.3564"}
{"text": "Oct 17 .[ Epub ahead of print ] .Rationale .The CRASH-2 trial demonstrated that the use of TXA reduced mortality in civilian trauma patients .", "label": "", "metadata": {}, "score": "54.511673"}
{"text": "Thirty - nine per cent of the patients suffered from CAD , 23 % had PAD , 29 % had diabetes mellitus , 30.5 % had chronic renal insufficiency , and 30.7 % suffered from COPD while 15 % exhibited impaired LV function .", "label": "", "metadata": {}, "score": "54.5922"}
{"text": "July 13 , 2009 .Sucampo issued positive results from a phase II trial of cobiprostone for the prevention of gastric ulcers and other gastrointestinal injuries associated with non - steroidal anti - inflammatory drugs ( NSAIDs ) .", "label": "", "metadata": {}, "score": "54.658257"}
{"text": "Primary endpoint of the phase I part : .To determine the maximal tolerated dose ( MTD ) and dose limiting toxicities ( DLTs ) of increased doses of IV clofarabine administered either daily from D1 to D5 for a 28 to 56 day - course or every other day from D1 to D10 for a 28 to 56 day - course .", "label": "", "metadata": {}, "score": "54.710953"}
{"text": "10 , pp .1509 - 1515 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. Makay , Z. T\u00fcrky\u0131lmaz , M. Duman , and E. \u00dcnsal , \" Mean platelet volume in Henoch - Sch\u00f6nleinpurpura : relationship to gastrointestinal bleeding , \" Clinical Rheumatology , vol .", "label": "", "metadata": {}, "score": "54.83486"}
{"text": "infusion of placebo before the same 27-day period of oral treatment with esomeprazole .Regulatory filings are currently under review by the FDA and EMEA .", "label": "", "metadata": {}, "score": "54.971214"}
{"text": "Cardiac tamponade occurred in 13 patients ( 3.9 % ) , shock was seen in 26 patients ( 7.9 % ) , and urgent cardiothoracic surgery was necessary in 4 patients ( 1.2 % ) .", "label": "", "metadata": {}, "score": "54.97785"}
{"text": "The subjects receiving the 54 mcg dose experienced a 50.0 % reduction in the overall incidence of gastric ulcers when compared to the placebo arm .", "label": "", "metadata": {}, "score": "55.161774"}
{"text": "WARNINGS : ( A ) DISCONTINUING ELIQUIS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE , ( B ) SPINAL / EPIDURAL HEMATOMA .", "label": "", "metadata": {}, "score": "55.246105"}
{"text": "307 - 312 , 2011 .View at Google Scholar \u00b7 View at Scopus .S. Toggweiler , R. Gurvitch , J. Leipsic et al . , \" Percutaneous aortic valve replacement : vascular outcomes with a fully percutaneous procedure , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "55.270203"}
{"text": "622 - 626 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. J. Hendra , G. A. Oswald , and J. S. Yudkin , \" Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure , \" Diabetes Research and Clinical Practice , vol .", "label": "", "metadata": {}, "score": "55.34343"}
{"text": "The use of next - generation devices combined with increasing expertise in the technique and appropriate patient selection has resulted in encouraging outcomes with regard to both safety and efficacy .", "label": "", "metadata": {}, "score": "55.375698"}
{"text": "Antifribrinolytic drugs can prevent clot breakdown and thus reduce blood loss in surgery 3 .In elective surgery , TXA reduces blood transfusion by a third , without significant reduction in mortality or increased postoperative complications 3 .", "label": "", "metadata": {}, "score": "55.395687"}
{"text": "Cochrane Database Syst Rev. 2007;4:CD001886 .[Links ] .CRASH-2 trial collaborators .Effects of tranexamic acid on death , vascular occlusive events , and blood transfusion in trauma patients with significant haemorrhage ( CRASH-2 ) : a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "55.675266"}
{"text": "The CSEP at 30 days was reached in 30.9 % ; major vascular complications were observed in 14.9 % while life - threatening bleeding occurred in 20.6 % .", "label": "", "metadata": {}, "score": "55.859203"}
{"text": "363 , no .17 , pp . 1597 - 1607 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Cribier , H. Eltchaninoff , A. Bash et al . , \" Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis : first human case description , \" Circulation , vol .", "label": "", "metadata": {}, "score": "56.120415"}
{"text": "The incidence of major vascular complications ranges between 5.6 and 17.3 % [ 7 , 8 , 12 - 16 ] .Such complications not only lead to increased morbidity and impaired quality of life but also to significantly higher 30-day mortality [ 16 ] .", "label": "", "metadata": {}, "score": "56.16649"}
{"text": "It has been speculated that RDW is an integrative measure of underlying pathologic conditions leading to increased oxidative stress and subclinical inflammation ; however , further studies are needed .", "label": "", "metadata": {}, "score": "56.219296"}
{"text": "12 , pp .1824 - 1829 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. G\u00e9n\u00e9reux , S. J. Head , N. M. van Mieghem et al . , \" Clinical outcomes after transcatheter aortic valve replacement using Valve Academic Research Consortium definitions .", "label": "", "metadata": {}, "score": "56.533463"}
{"text": "CRASH-2 Trial Collaborators : Effects of tranexamic acid on death , vascular occlusive events , and blood transfusion in trauma patients with significant haemorrhage ( CRASH-2 ) a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "56.572906"}
{"text": "A multidisciplinary Heart Team comprising two interventional cardiologists , a cardiac surgeon , and an anesthesiologist evaluated all patients .All patients provided written informed consent for the procedures .", "label": "", "metadata": {}, "score": "56.59097"}
{"text": "\" Once a VTE has occurred , approximately 33 percent of patients may experience a recurrence within 10 years .\" The marketing authorization for Eliquis follows the positive opinion issued by the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency , and is supported by two pivotal Phase 3 clinical trials , AMPLIFY and AMPLIFY - EXT .", "label": "", "metadata": {}, "score": "56.688545"}
{"text": "113 - 118 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R.-J. Nuis , N. M. van Mieghem , R. M. van Der Boon et al . , \" Effect of experience on results of transcatheter aortic valve implantation using a medtronic CoreValve system , \" American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "56.823456"}
{"text": "Triglyceride lowering with Epanova was previously observed in two large , placebo - controlled , randomized , double - blind , Phase III studies involving 748 Crohn 's disease patients with normal triglyceride levels for 52 weeks , approximately 400 of which were treated with Epanova for remission of disease .", "label": "", "metadata": {}, "score": "56.889977"}
{"text": "Rationale .TXA is expected to reduce bleeding by preventing clot breakdown .However , despite reducing all - cause mortality , the CRASH-2 trial showed no difference in transfusion requirements between the TXA and placebo groups .", "label": "", "metadata": {}, "score": "56.98154"}
{"text": "( b ) Major vascular complications in TAVI patients , univariate analysis , and multivariate analysis .( c ) Life - threatening bleeding events in TAVI patients , univariate analysis , and multivariate analysis .", "label": "", "metadata": {}, "score": "57.102448"}
{"text": "J Trauma .[Links ] .Hess JR , Brohi K , Dutton RP , Hauser CJ , Holcomb JB , Kluger Y , et al .", "label": "", "metadata": {}, "score": "57.11033"}
{"text": "743 - 750 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. M. Sinning , M. Horack , E. Grube et al . , \" The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation : results from the German Transcatheter Aortic Valve Interventions Registry , \" American Heart Journal , vol .", "label": "", "metadata": {}, "score": "57.1646"}
{"text": "The mean age was 56.7 years and 91.7 percent of randomized patients had unprovoked VTE events .In the study , both doses of Eliquis were statistically superior to placebo in the primary endpoint of symptomatic , recurrent VTE ( nonfatal DVT or nonfatal PE ) or all - cause death .", "label": "", "metadata": {}, "score": "57.292988"}
{"text": "It is possible that there is a decrease in platelet size with increasing shear stress present in aortic stenosis , resulting in low MPV indices .", "label": "", "metadata": {}, "score": "57.460903"}
{"text": "An increased rate of stroke was observed following discontinuation of ELIQUIS in clinical trials in patients with nonvalvular atrial fibrillation .If anticoagulation with ELIQUIS must be discontinued for a reason other than pathological bleeding , coverage with another anticoagulant should be strongly considered .", "label": "", "metadata": {}, "score": "57.540543"}
{"text": "205 - 213 , 1983 .View at Google Scholar \u00b7 View at Scopus .J. F. Martin , E. A. Trowbridge , G. Salmon , and J. Plumb , \" The biological significance of platelet volume : its relationship to bleeding time , platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "57.65381"}
{"text": "Similarly , in - hospital MI was noted in 3 patients while 13 patients ( 3.9 % ) died during their hospital stay .Renal replacement therapy was required in 18 patients ( 5.3 % ) while a permanent pacemaker was implanted post - TAVI in 50 patients ( 13.2 % ) .", "label": "", "metadata": {}, "score": "57.683807"}
{"text": "Interestingly , our group has recently shown an abnormally high activated clotting time in subjects undergoing TAVI [ 38 ] ; this could also be an indicator of platelet dysfunction which is possibly vWF - mediated and contributes to bleeding tendency in patients with severe AS .", "label": "", "metadata": {}, "score": "57.93778"}
{"text": "Complete hematological response at week 32 was seen in 24 % and 9 % of Jakafi and BAT patients , respectively .Researchers concluded that Jakafi was well tolerated and improved patients ' ability to control hematocrit levels without phlebotomy , as well as reduced spleen volume .", "label": "", "metadata": {}, "score": "58.03135"}
{"text": "Failure of percutaneous closure was observed in 27 patients ( 8.2 % ) .Device success was achieved in 306 patients ( 92.7 % ) .", "label": "", "metadata": {}, "score": "58.12938"}
{"text": "CRASH-2 collaborators .The importance of early treatment with tranexamic acid in bleeding trauma patients : an exploratory analysis of the CRASH-2 randomised controlled trial .", "label": "", "metadata": {}, "score": "58.13228"}
{"text": "In conclusion the authors said that \" enoxaparin is preferable to unfractionated heparin for venous thromboembolism prophylaxis in this high- risk medically ill patient in view of its better clinical benefits to risk ratio and convenience of once daily administration . \"", "label": "", "metadata": {}, "score": "58.152454"}
{"text": "March 26 , 2012 .POZEN released results from two phase III trials of PA32540 , a coordinated - delivery tablet of immediate - release omeprazole and delayed release aspirin , under development for the secondary prevention of cardiovascular disease in subjects at risk for aspirin - induced ulcers .", "label": "", "metadata": {}, "score": "58.24086"}
{"text": "Significant determinants identified from univariate analysis were studied in a forward stepwise multivariate logistic regression model .Variables were entered into the regression model if their .", "label": "", "metadata": {}, "score": "58.39039"}
{"text": "672 - 679 , 1999 .View at Google Scholar \u00b7 View at Scopus .P. Bath , C. Algert , N. Chapman , and B. Neal , \" Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease , \" Stroke , vol .", "label": "", "metadata": {}, "score": "58.49216"}
{"text": "Limitations . \u00b7Retrospective study design performed in a single center ; . \u00b7Variation in practice during the study period ( January 2009 to December 2010 ) may have occurred .", "label": "", "metadata": {}, "score": "58.52606"}
{"text": "J Trauma .[Links ] .Henry DA , Carless PA , Moxey AJ , O'Connell D , Stokes BJ , McClelland B , et al .", "label": "", "metadata": {}, "score": "58.842186"}
{"text": "Increased Risk of Stroke with Discontinuation of ELIQUIS in Patients with Nonvalvular Atrial Fibrillation : Discontinuing ELIQUIS in the absence of adequate alternative anticoagulation increases the risk of thrombotic events .", "label": "", "metadata": {}, "score": "58.875957"}
{"text": "Total health care resource utilization and cost - effectiveness [ Time Frame : 6 and 12 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.883232"}
{"text": "Detailed Description .This is a prospective , non - randomized , open - label , non - inferiority comparative effectiveness outcomes trial comparing clopidogrel EMs ( confirmed by CYP2C19 genotype)and receiving clopidogrel at 75 mg / day with subjects receiving prasugrel at 5 and/or 10 mg / day .", "label": "", "metadata": {}, "score": "58.93639"}
{"text": "However , in the PRAGMATIC study , a learning curve effect was not identified as an independent predictor of access site complications , possibly secondary to the high technical skills of the operators with other complex catheter - based procedures before embarking on a TAVI program .", "label": "", "metadata": {}, "score": "59.044765"}
{"text": "Observational Model : Cohort Time Perspective : Prospective .Target Follow - Up Duration .Not Provided .Biospecimen .Retention : Samples With DNA .", "label": "", "metadata": {}, "score": "59.052135"}
{"text": "Also we lack information on frailty status and platelet aggregation studies .However , we were interested in identifying prognostic markers which can be easily measured in clinical practice rather than those which are only available in a research setting .", "label": "", "metadata": {}, "score": "59.174576"}
{"text": "October 27 , 2008 .AstraZeneca released positive results from a clinical trial of Nexium ( esomeprazole ) for the treatment of peptic ulcer re - bleeding .", "label": "", "metadata": {}, "score": "59.316063"}
{"text": "View at Publisher \u00b7 View at Google Scholar .N. M. van Mieghem , D. Tchetche , A. Chieffo et al . , \" Incidence , predictors , and implications of access site complications with transfemoral transcatheter aortic valve implantation , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "59.455307"}
{"text": "In spite of the increasing expertise and technological advancements , vascular and bleeding complications after TF - TAVI are still present .A low baseline MPV was shown for the first time to be a significant predictor of CSEP , major vascular complications , and life - threatening bleeding in subjects undergoing TF - TAVI .", "label": "", "metadata": {}, "score": "59.480213"}
{"text": "The large sample size resulted in a well - balanced study with respect to baseline prognostic factors between groups ; . \u00b7Relatively inexpensive drug , safe and of easy administration ; . \u00b7", "label": "", "metadata": {}, "score": "59.508057"}
{"text": "Consider the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis .CONTRAINDICATIONS .Active pathological bleeding .Severe hypersensitivity reaction to ELIQUIS ( apixaban ) ( e.g. , anaphylactic reactions ) .", "label": "", "metadata": {}, "score": "59.70656"}
{"text": "Larger platelets also demonstrate greater aggregability in response to ADP and decreased inhibition of aggregation by prostacyclin in vitro [ 31 , 32 ] , thus leading to increased thrombotic activity .", "label": "", "metadata": {}, "score": "59.830376"}
{"text": "A beneficial effect of smaller sheaths has been shown in TF - TAVI [ 39 , 41 , 42 ] .With regard to the association with history of MI , this is probably secondary to the presence of severe and diffuse atherosclerosis that predisposes these patients to major vascular complications .", "label": "", "metadata": {}, "score": "60.086273"}
{"text": "The preliminary data also showed dose - dependent increases in plasma EPA and DHA levels with Epanova .We look forward to completing a comprehensive analysis of the study and aim to present the complete data set at an upcoming scientific meeting .", "label": "", "metadata": {}, "score": "60.13594"}
{"text": "Each treatment was separated by a 14 day washout period .The primary endpoint was the percent inhibition of platelet aggregation ( IPA ) after morning dosing on day seven of each period .", "label": "", "metadata": {}, "score": "60.38876"}
{"text": "18 , pp .1686 - 1695 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. P. Kappetein , S. J. Head , P. G\u00e9n\u00e9reux et al . , \" Updated standardized endpoint definitions for transcatheter aortic valve implantation : the Valve Academic Research Consortium-2 consensus document , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "60.398117"}
{"text": "178 - 188 , 2001 .View at Google Scholar \u00b7 View at Scopus .N. Takahashi , K. Tanabe , H. Yoshitomi et al . , \" Impairment of platelet retention rate in patients with severe aortic valve stenosis , \" Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "60.445038"}
{"text": "The subjects received treatment with either PA32540 or 325 mg enteric - coated aspirin once daily .The primary endpoint , a significant reduction in the cumulative incidence of gastric ulcers following administration of PA32540 versus 325 mg enteric - coated aspirin over six months , was met in both studies .", "label": "", "metadata": {}, "score": "60.71112"}
{"text": "Furthermore , 85.1 % of subjects on enteric - coated aspirin reported adverse events compared to 71.8 % of subjects on PA32540 .The drug was well tolerated .", "label": "", "metadata": {}, "score": "60.755486"}
{"text": "Results and Discussion .Study Population .The baseline characteristics of the overall study population are outlined in Table 1 .In total , 330 subjects were assessed with a median age of 81 years and a median logistic Euroscore of 18.54 .", "label": "", "metadata": {}, "score": "60.810013"}
{"text": "19 , pp .2403 - 2418 , 2012 .View at Google Scholar .R. Gurvitch , S. Toggweiler , A. B. Willson et al . , \" Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium ( VARC ) guidelines , \" EuroIntervention , vol .", "label": "", "metadata": {}, "score": "60.813828"}
{"text": "At 48 weeks , 91 % of the Jakafi group had maintained their response .Sixty percent of the Jakafi cohort and 20 % of the BAT group achieved hematocrit control without phlebotomy .", "label": "", "metadata": {}, "score": "61.046898"}
{"text": "102 - 10 .e1 , 2012 .View at Google Scholar Allocation : Non - Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "61.13998"}
{"text": "Interestingly , platelet dysfunction has been implicated in patients with aortic stenosis ( AS ) .Vincentelli et al .demonstrated that the association between aortic stenosis and gastrointestinal bleeding is secondary to a reduction in the proportion of high - molecular - weight von Willebrand factor ( vWF ) multimers and such impaired distribution of the multimers could be restored following valve replacement [ 35 ] .", "label": "", "metadata": {}, "score": "61.49382"}
{"text": "The results may have been driven by a few or even a single center .The study did not report on outcome and patient characteristic data according to each major participating country . \u00b7", "label": "", "metadata": {}, "score": "61.530838"}
{"text": "Fifty - eight subjects were taking warfarin prior to the procedure .Coagulation times were within normal limits in patients not taking warfarin . while a 28 Fr sheath was used in 1 patient .", "label": "", "metadata": {}, "score": "61.62877"}
{"text": "View at Google Scholar \u00b7 View at Scopus . H. Giles , R. E. A. Smith , and J. F. Martin , \" Platelet glycoprotein IIb - IIIa and size are increased in acute myocardial infarction , \" European Journal of Clinical Investigation , vol .", "label": "", "metadata": {}, "score": "61.882065"}
{"text": "The TBE - CiTE Journal Club performed a critical appraisal of the most important evidence recently published on the topic and provides evidence - based recommendations on the use of TXA in trauma .", "label": "", "metadata": {}, "score": "61.976265"}
{"text": "The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million , with approximately 35 million of those diagnosed with hypertriglyceridemia ( triglycerides greater than 200mg / dL ) and an estimated 5 million with very high triglyceride levels ( triglycerides greater than 500mg / dL ) .", "label": "", "metadata": {}, "score": "61.993492"}
{"text": "As regards RDW , it is another novel haematologic parameter and a measure of heterogeneity in erythrocyte size reported as part of a standard complete blood count .", "label": "", "metadata": {}, "score": "62.004112"}
{"text": "Female patient undergoing urgent or elective PCI or undergoing diagnostic angiography to evaluate ischemic symptoms with the possibility of PCI .Exclusion Criteria : .Unable to provide informed consent .", "label": "", "metadata": {}, "score": "62.352898"}
{"text": "This information does not represent a Lupus Research Institute endorsement of any listed study .It is merely a notice that the study is available .", "label": "", "metadata": {}, "score": "62.398018"}
{"text": "The recommended dose of Eliquis for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily .Adjudicated ISTH major gastrointestinal bleeding occurred in 1 ( 0.1 percent ) Eliquis -treated patient at the 5 mg twice daily dose , no patients at the 2.5 mg twice daily dose , and 1 ( 0.1 percent ) placebo - treated patient .", "label": "", "metadata": {}, "score": "62.40267"}
{"text": "AMPLIFY .The mean age was 56.9 years and 89.8 percent of randomized patients had unprovoked VTE events .In the study , Eliquis was shown to be non - inferior to enoxaparin / warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE ( nonfatal DVT or nonfatal PE ) or VTE - related death .", "label": "", "metadata": {}, "score": "62.42848"}
{"text": "5 , pp .443 - 460 , 1983 .View at Google Scholar \u00b7 View at Scopus .P. J. Khatri , J. G. Webb , J. Rod\u00e9s - Cabau et al . , \" Adverse effects associated with transcatheter aortic valve implantation : a meta - analysis of contemporary studies , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "62.59246"}
{"text": "5 , pp .556 - 563 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Mussardo , A. Latib , A. Chieffo et al . , \" Periprocedural and short - term outcomes of transfemoral transcatheter aortic valve implantation with the Sapien XT as compared with the Edwards Sapien valve , \" JACC , vol .", "label": "", "metadata": {}, "score": "62.739983"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study .", "label": "", "metadata": {}, "score": "62.86246"}
{"text": "CRASH-2 used a small dose of TXA ( 2 to 10 times lower than those used in cardiac surgery where TXA has been implicated with postoperative seizures 5 .", "label": "", "metadata": {}, "score": "62.92146"}
{"text": "Eliquis is approved for the treatment of DVT and PE , and prevention of recurrent DVT and PE in the European Union .Eliquis is not approved for this indication in the United States .", "label": "", "metadata": {}, "score": "62.93055"}
{"text": "All measurements were performed at the hospital 's central laboratory .MPV measurement was performed by impedance counting using Sismex M2100 Haematologic Analyzer .The normal laboratory reference range for MPV is between 9.1 and 12.5 fL. Secondary endpoints included major vascular complications and life - threatening bleeding .", "label": "", "metadata": {}, "score": "63.054985"}
{"text": "Furthermore , Epanova appeared safe and well tolerated , with discontinuation rates due to adverse events , primarily gastrointestinal , ranging from 5 % to 7 % across all dosing groups .", "label": "", "metadata": {}, "score": "63.065987"}
{"text": "64 , no .4 , pp .542 - 546 , 1978 .View at Google Scholar \u00b7 View at Scopus .J. A. Jakubowski , B. Adler , and C. B. Thompson , \" Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction , \" Journal of Laboratory and Clinical Medicine , vol .", "label": "", "metadata": {}, "score": "63.189247"}
{"text": "Among other risks , there can be no guarantee that the approval of these additional indications in Europe will lead to increased commercial success or that Eliquis will be approved for these additional indications in the U.S. or in other countries .", "label": "", "metadata": {}, "score": "63.286144"}
{"text": "2011;377(9771):1096 - 101 , 1101.e1 - 2 . [Links ] .Morrison JJ , Dubose JJ , Rasmussen TE , Midwinter MJ .Military application of tranexamic acid in trauma emergency resuscitation ( MATTERs ) study .", "label": "", "metadata": {}, "score": "63.352665"}
{"text": "Question .Does Tranexamic acid ( 1 g load , then 1 g over 8h ) reduce mortality and blood transfusion without increasing vascular occlusive complications in trauma patients with or at risk of significant bleeding ?", "label": "", "metadata": {}, "score": "63.584396"}
{"text": "The objective of this study was to assess whether low MPV is an indicator of major vascular and bleeding complications following TF - TAVI .Methods .", "label": "", "metadata": {}, "score": "63.786594"}
{"text": "Fourteen patients will be enrolled at the RD using the selected dosing in each cohort , for an enrollment period of 12 months .Each patient may receive up to 8 courses , every 4 to 8 weeks in a D1-D5 schedule or every other day from D1 to D10 .", "label": "", "metadata": {}, "score": "63.801384"}
{"text": "Patients should be made aware of signs or symptoms of blood loss and instructed to immediately report to an emergency room .Discontinue ELIQUIS in patients with active pathological hemorrhage .", "label": "", "metadata": {}, "score": "63.90026"}
{"text": "The Boxed Warning concerns patients who do not effectively metabolize the drug ( i.e. \" poor metabolizers \" ) and therefore may not receive the full benefits of the drug .", "label": "", "metadata": {}, "score": "63.906063"}
{"text": "The event rate for clopidogrel extensive metabolizers alone has never been directly compared to prasugrel .Upon review of data extracted from Medco 's integrated claims database , the \" real - world \" prescribing practice of physicians for Plavix and Effient varies significantly from the narrow indication of ACS studied in the TRITON - TIMI 38 study , and from the current Effient approved labeling .", "label": "", "metadata": {}, "score": "63.99184"}
{"text": "It is a nonrandomized retrospective study .It was not possible to assess inter - operator variability due to the high correlation with variables entered in the analysis .", "label": "", "metadata": {}, "score": "64.10474"}
{"text": "Among medically - ill patients , stroke patients are at an increased risk for developing VTE .Without VTE prophylaxis , up to 75 % of patients with hemiplegia following stroke develop Deep - Vein Thrombosis ( DVT ) and 20 % develop Pulmonary Embolism ( PE ) .", "label": "", "metadata": {}, "score": "64.18642"}
{"text": "Patients with AML and bone marrow blasts count of 20 - 30 % , if candidates to intensive AML type chemotherapy .Known hypersensitivity to clofarabine or excipients .", "label": "", "metadata": {}, "score": "64.2079"}
{"text": "PREGNANCY CATEGORY B .There are no adequate and well - controlled studies of ELIQUIS in pregnant women .Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery .", "label": "", "metadata": {}, "score": "64.279495"}
{"text": "These findings are consistent with the results from the Paris - Rotterdam - Milano - Toulouse in Collaboration ( PRAGMATIC ) study [ 39 ] whereby female sex and sheath size were independent predictors for major vascular complications .", "label": "", "metadata": {}, "score": "64.66136"}
{"text": "157 - 161 , 1996 .View at Google Scholar \u00b7 View at Scopus .C. B. Thompson , J. A. Jakubowski , and P. G. Quinn , \" Platelet size as a determinant of platelet function , \" Journal of Laboratory and Clinical Medicine , vol .", "label": "", "metadata": {}, "score": "64.75136"}
{"text": "59 , pp .2317 - 2326 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. M. Frojmovic and J. G. Milton , \" Human platelet size , shape , and related functions in health and disease , \" Physiological Reviews , vol .", "label": "", "metadata": {}, "score": "64.77712"}
{"text": "The antithrombotic regimen varied slightly interindividually .Generally , patients were loaded with aspirin and clopidogrel ( 300 mg followed by 75 mg daily ) at least 1 day before the intervention .", "label": "", "metadata": {}, "score": "65.16564"}
{"text": "As with all anticoagulants , the most frequently reported side effect for enoxaparin is bleeding .Clinical indications for enoxaparin may vary from one country to another .", "label": "", "metadata": {}, "score": "65.192856"}
{"text": "63 - 69 , 1988 .View at Google Scholar \u00b7 View at Scopus .C. B. Thompson and J. A. Jakubowski , \" The pathophysiology and clinical relevance of platelet heterogeneity , \" Blood , vol .", "label": "", "metadata": {}, "score": "65.410614"}
{"text": "The significant reduction of VTE risk with Clexane(R ) / Lovenox(R ) versus UFH was maintained when therapy was initiated within 24 hours or 24 hours-48 hours after stroke onset .", "label": "", "metadata": {}, "score": "65.50598"}
{"text": "All the subjects received 500 mg of naproxen twice a day .There were four treatment cohorts : one cohort received placebo while the other three cohorts received 18 mcg of cobiprostone either once , twice or three times a day ( daily totals of 18 , 36 or 54 mcg , respectively ) .", "label": "", "metadata": {}, "score": "65.63166"}
{"text": "The efficacy of prasugrel and clopidogrel have been compared head - to - head in the TRITON - TIMI 38 study .This trial enrolled 13,608 ACS patients scheduled for PCI and compared prasugrel ( 60-mg loading dose and then 10-mg daily maintenance dose ) against clopidogrel ( 300-mg/75-mg ) , both in combination with aspirin .", "label": "", "metadata": {}, "score": "65.80055"}
{"text": "The authors declare that there is no conflict of interests .References .4 , no . 2 , pp .242 - 249 , 2008 .", "label": "", "metadata": {}, "score": "65.86863"}
{"text": "Untreated , PV can lead to a thickening of the blood and , eventually , heart attack and stroke .Phlebotomy is one treatment deployed in which blood is removed from the body .", "label": "", "metadata": {}, "score": "66.19173"}
{"text": "As with other anticoagulants , use with extreme caution in patients with conditions that increase the risk of hemorrhage .Dosage adjustment is recommended in patients with severe renal impairment .", "label": "", "metadata": {}, "score": "66.28822"}
{"text": "The association between PAD and bleeding events is probably secondary to difficult vascular access in patients with PAD , resulting in more bleeding .This is in line with the current data on TAVI patients whereby the presence of PAD has been shown to be a predictor not only of major vascular complications but also of mortality in patients with percutaneous and surgical TAVI [ 43 ] .", "label": "", "metadata": {}, "score": "66.29727"}
{"text": "No affiliation to a national insurance scheme directly or to an equivalent system .Chemotherapy , radiation therapy , or immunotherapy other than as specified in the protocol .", "label": "", "metadata": {}, "score": "66.35861"}
{"text": "Risk of Having a Venous ThromboEmbolism ( VTE ) is Reduced by a Significant 43 % in Acute Ischemic Stroke Patients Treated With Clexane(R ) / Lovenox(R ) .", "label": "", "metadata": {}, "score": "66.47118"}
{"text": "Anticoagulants and Antiplatelet Agents : Coadministration of antiplatelet agents , fibrinolytics , heparin , aspirin , and chronic NSAID use increases the risk of bleeding .", "label": "", "metadata": {}, "score": "66.506905"}
{"text": "Similarly , only 13 % of new Effient users have evidence of an ACS event within 6 months of a new prescription for that agent .", "label": "", "metadata": {}, "score": "66.83991"}
{"text": "Other Name : EVOLTRA \u00ae .Experimental : Cohort B .Clofarabine treatment at D1 , D3 , D5 , D8 , D10 .Drug : Clofarabine .", "label": "", "metadata": {}, "score": "66.90181"}
{"text": "The objective of this study was to assess whether low MPV is an indicator of combined safety endpoint and major vascular and bleeding complications following percutaneous transfemoral aortic valve implantation ( TF - TAVI ) .", "label": "", "metadata": {}, "score": "66.903305"}
{"text": "If the platelet count falls below 100,000/mm3 , LOVENOX(R ) should be discontinued .Cases of heparin - induced thrombocytopenia have been observed in clinical practice .", "label": "", "metadata": {}, "score": "66.9748"}
{"text": "Discussion .The main findings of this study were as follows .( 1 ) Baseline MPV is an independent predictor of CSEP at thirty days , as well as major vascular complications and life - threatening bleeding events following TF - TAVI .", "label": "", "metadata": {}, "score": "67.27229"}
{"text": "The standard access route was the transfemoral ( TF ) approach ; the transapical , transaxillary / subclavian , or transaortic approach was considered whenever the TF approach was found to be inappropriate by the Heart Team .", "label": "", "metadata": {}, "score": "67.51682"}
{"text": "In patients already taking ELIQUIS at a dose of 2.5 mg twice daily , avoid coadministration with strong dual inhibitors of CYP3A4 and P - gp .", "label": "", "metadata": {}, "score": "67.63165"}
{"text": "If ELIQUIS must be discontinued for a reason other than pathological bleeding , consider coverage with another anticoagulant .Bleeding Risk : ELIQUIS increases the risk of bleeding and can cause serious , potentially fatal bleeding .", "label": "", "metadata": {}, "score": "67.63423"}
{"text": "1361 - 1367 , 2012 .View at Google Scholar .G. L. Buchanan , A. Chieffo , M. Montorfano et al . , \" The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN and Medtronic CoreValve ReValving System devices : the Milan registry , \" EuroIntervention , vol .", "label": "", "metadata": {}, "score": "67.6449"}
{"text": "Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels .About Omthera Pharmaceuticals , Inc. .", "label": "", "metadata": {}, "score": "67.74245"}
{"text": "Interestingly , while sheath size was significant in univariate analysis , it lost its significance on performing multivariate logistic regression analysis , indicating that MPV is a stronger predictor of vascular complications .", "label": "", "metadata": {}, "score": "68.022026"}
{"text": "41 - 48 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. E. St\u00e4hli , R. B\u00fcnzli , J. Gr\u00fcnenfelder et al . , \" Transcatheter aortic valve implantation ( TAVI ) outcome according to standardized endpoint definitions by the Valve Academic Research Consortium ( VARC ) , \" Journal of Invasive Cardiology , vol .", "label": "", "metadata": {}, "score": "68.10497"}
{"text": "Among these are vascular and bleeding complications which commonly coexist and remain important limitations of TAVI performed via the transfemoral route [ 5 , 9 , 10 ] .", "label": "", "metadata": {}, "score": "68.2967"}
{"text": "Novel risk factors are therefore desirable .Platelets are circulating , anucleate , disc - shaped cells that help to maintain the integrity of blood vessels through adequate haemostasis [ 18 ] .", "label": "", "metadata": {}, "score": "68.36995"}
{"text": "MPV is an inexpensive and readily available haematologic parameter that is routinely reported with complete blood count and consequently could serve as a useful adjunctive tool in identifying subjects who are at high risk of bleeding following TF - TAVI .", "label": "", "metadata": {}, "score": "69.19835"}
{"text": "The DLa will be the following : .DL1a - 2.5mg / m2/d , DL2a - 6.5mg / m2/d , DL3a - 8.5mg / m2/d , DL4a - 11.5mg / m2/d ( In case of activation of the DL4 step ) .", "label": "", "metadata": {}, "score": "69.26889"}
{"text": "The DLa will be the following : .DL1a - 2.5mg / m2/d , DL2a - 6.5mg / m2/d , DL3a - 8.5mg / m2/d , DL4a - 11.5mg / m2/d ( In case of activation of the DL4 step ) .", "label": "", "metadata": {}, "score": "69.26889"}
{"text": "35 - 46 , 2013 .View at Google Scholar .S. Toggweiler and J. G. Webb , \" Challenges in transcatheter aortic valve implantation , \" Swiss Medical Weekly , vol .", "label": "", "metadata": {}, "score": "69.4333"}
{"text": "With regard to MPV , a low MPV was independently associated with increased vascular and bleeding complications , these being the major determinants of CSEP in our TAVI cohort .", "label": "", "metadata": {}, "score": "69.554474"}
{"text": "271 - 276 , 1985 .View at Google Scholar \u00b7 View at Scopus .L. Vizioli , S. Muscari , and A. Muscari , \" The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases , \" International Journal of Clinical Practice , vol .", "label": "", "metadata": {}, "score": "69.712875"}
{"text": "The primary objective of ESPRIT is to evaluate the efficacy of adding Epanova ( 2 gram or 4 gram daily ) to statin monotherapy for lowering non - HDL - cholesterol .", "label": "", "metadata": {}, "score": "69.75016"}
{"text": "Approximately 100,000 patients in the United States are living with PV and approximately 25 percent of patients with PV develop resistance to or intolerance of hydroxyurea .", "label": "", "metadata": {}, "score": "69.7661"}
{"text": "Absence of pregnancy or lactation in female patients ( Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment ) .", "label": "", "metadata": {}, "score": "69.78403"}
{"text": "There is neither scientific rationale for reversal nor experience with systemic hemostatics ( desmopressin and aprotinin ) in individuals receiving apixaban .Use of procoagulant reversal agents such as prothrombin complex concentrate , activated prothrombin complex concentrate , or recombinant factor VIIa may be considered but has not been evaluated in clinical studies .", "label": "", "metadata": {}, "score": "70.33231"}
{"text": "The PREVAIL trial is the first large - scale , multinational , prospective , randomized , open - label study , which enrolled 1,762 stroke patients ( stratified by NIH Stroke Scale Score ) in over 15 countries .", "label": "", "metadata": {}, "score": "70.56766"}
{"text": "Saliva .Sampling Method .Non - Probability Sample .Study Population .Adults between the ages of 18 and 75 with newly initiated clopidogrel ( Plavix ) or prasugrel ( Effient ) therapy .", "label": "", "metadata": {}, "score": "70.64272"}
{"text": "Other Name : EVOLTRA \u00ae .Detailed Description : .The study is an open - label , 3 + 3 dose - escalation , phase I / II study .", "label": "", "metadata": {}, "score": "70.67924"}
{"text": "In addition there were significant differences in baseline characteristics of the patients doing TAVI via the TF access versus non - TF access .Non - TF access patients had less favorable clinical characteristics with significantly increased incidence of coronary artery disease , chronic obstructive pulmonary disease , and chronic kidney disease , resulting in significantly higher logistic Euroscore and Society of Thoracic Surgeons Predicted Risk of Mortality ( STS - PROM ) .", "label": "", "metadata": {}, "score": "70.67975"}
{"text": "Jakafi was also successful in reducing spleen volume and improving PV symptoms .Researchers in this study enrolled PV patients who were phlebotomy dependent and intolerant or resistant to hydroxyurea .", "label": "", "metadata": {}, "score": "70.68384"}
{"text": "The variability of clopidogrel response is associated with variability in CYP enzyme genetic expression and activity , primarily CYP2C19 which is principally responsible for the conversion of clopidogrel into its active metabolite .", "label": "", "metadata": {}, "score": "70.881874"}
{"text": "PE is a blood clot blocking one or more vessels in the lungs .DVT causes multiple symptoms including pain , swelling , and redness , and more importantly , can progress to PE , which carries the risk of sudden death .", "label": "", "metadata": {}, "score": "70.92461"}
{"text": "This active thiol metabolite inhibits adenosine diphosphate ( ADP)-induced platelet aggregation by blocking the platelet P2Y12 receptor , resulting in a reduction of ADP - mediated platelet aggregation .", "label": "", "metadata": {}, "score": "71.02985"}
{"text": "Rationale .Excessive hyperfibrinolysis is present in some trauma patients with bleeding and is associated with increased risk of death .Antifibrinolytic drugs , particularly TXA , can prevent excessive clot breakdown and reduces blood transfusion in surgery .", "label": "", "metadata": {}, "score": "71.15178"}
{"text": "[Links ] .Syrovets T , Simmet T. Novel aspects and new roles for the serine protease plasmin .Cell Mol Life Sci .[", "label": "", "metadata": {}, "score": "71.3197"}
{"text": "VTE is also a common complication among individuals who have experienced an acute ischemic stroke ( AIS ) , a population of medically - ill patients at particularly high - risk for VTE .", "label": "", "metadata": {}, "score": "71.39313"}
{"text": "AMPLIFY- EXT .As described in the SmPC , in the AMPLIFY - EXT study a total of 2,482 patients were randomized to treatment with Eliquis 2.5 mg twice daily orally , Eliquis 5 mg twice daily orally , or placebo for 12 months after completing six to 12 months of initial anticoagulant treatment .", "label": "", "metadata": {}, "score": "71.41557"}
{"text": "This is comparable to the major vascular complication rate seen in our study population .To the best of our knowledge , this is the first study to report the correlation between MPV and CSEP mostly due to the impact on vascular and bleeding complications in patients undergoing TF - TAVI .", "label": "", "metadata": {}, "score": "71.6647"}
{"text": "Administer 1 g of TXA intravenously ( bolus over 10 minutes ) followed by the infusion of 1 g over 8 hours .REFERENCES .Sauaia A , Moore FA , Moore EE , Moser KS , Brennan R , Read RA , et al .", "label": "", "metadata": {}, "score": "72.18379"}
{"text": "About Hypertriglyceridemia .Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease .", "label": "", "metadata": {}, "score": "72.44205"}
{"text": "Larger platelets contain more granules and produce greater amounts of vasoactive and prothrombotic factors , such as thromboxane A2 , serotonin , and adenosine triphosphate ( ATP ) , thus resulting in greater haemostatic efficiency [ 19 , 20 ] .", "label": "", "metadata": {}, "score": "73.00145"}
{"text": "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established .DRUG INTERACTIONS .Strong Dual Inhibitors of CYP3A4 and P - gp : Inhibitors of CYP3A4 and P - gp increase exposure to apixaban and increase the risk of bleeding .", "label": "", "metadata": {}, "score": "73.02307"}
{"text": "Post - hoc receiver - operating characteristic ( ROC ) curve analysis was consequently performed to further analyze the relation between MPV and combined safety endpoint .", "label": "", "metadata": {}, "score": "73.51794"}
{"text": "Furthermore , in view of the mounting experience with alternative access routes ( transaxillary / subclavian , transaortic , and transapical ) , multimodal imaging assessment of the arterial tree may improve TAVI access strategy selection [ 44 ] .", "label": "", "metadata": {}, "score": "73.51921"}
{"text": "Provided signed written informed consent .Capable of understanding the investigational nature , potential risks and benefits of the study , and able to provide valid informed consent .", "label": "", "metadata": {}, "score": "73.67009"}
{"text": "In addition , the following haematological measurements were analyzed : white cell count , haemoglobin , red cell count , red blood cell distribution width , mean corpuscular volume , platelet count , and MPV .", "label": "", "metadata": {}, "score": "73.940506"}
{"text": "Study Design .A nonrandomized retrospective cohort study of all subjects undergoing TAVI in a European institution with established TAVI experience was conducted .Baseline patient characteristics , procedural details , and clinical outcome data from a series of 330 patients who underwent TAVI via the transfemoral approach at San Raffaele Scientific Institute , Milan , Italy , were collected since the introduction of the TAVI program from November 2007 to February 2012 .", "label": "", "metadata": {}, "score": "74.49581"}
{"text": "Alternatively , platelets with low MPV exhibit abnormal platelet adhesion .In fact , the interaction between vWF and platelet GP Ib plays a critical role in the initial phase of platelet adhesion , particularly under high shear stress [ 36 ] .", "label": "", "metadata": {}, "score": "74.6243"}
{"text": "Military Application of Tranexamic Acid in Trauma Emergency Resuscitation ( MATTERs ) Study .Morrison JJ , Dubose JJ , Rasmussen TE , Midwinter MJ .", "label": "", "metadata": {}, "score": "74.68877"}
{"text": "Studies have indicated that MPV is an indicator of platelet reactivity [ 19 , 24 , 25 ] .Larger platelets are denser and contain more alpha granules , dense granules , and lysosomes , which release prothrombotic factors [ 26 - 28 ] .", "label": "", "metadata": {}, "score": "74.88394"}
{"text": "69 - 72 , 1994 .View at Google Scholar \u00b7 View at Scopus .S. Karpatkin , Q. Khan , and M. Freedman , \" Heterogeneity of platelet function .", "label": "", "metadata": {}, "score": "74.94023"}
{"text": "Background .Vascular and bleeding complications remain important complications in patients undergoing percutaneous transfemoral transcatheter aortic valve implantation ( TF - TAVI ) .Platelets play an important role in bleeding events .", "label": "", "metadata": {}, "score": "75.90529"}
{"text": "185 - 261 , 1982 .View at Google Scholar \u00b7 View at Scopus .P. M. W. Bath and R. J. Butterworth , \" Platelet size : measurement , physiology and vascular disease , \" Blood Coagulation and Fibrinolysis , vol .", "label": "", "metadata": {}, "score": "76.40291"}
{"text": "The primary safety endpoints included symptomatic intracranial bleeding , major extracranial bleeding and all - cause mortality .About Venous Thromboembolism ( VTE ) .Venous thromboembolism is a general term used to describe the formation of a blood clot ( thrombus ) that blocks a vein .", "label": "", "metadata": {}, "score": "76.62718"}
{"text": "( Date:2/10/2016 ) ...YORK , Feb. 10 , 2016 Immune ... biopharmaceutical company , announced today that it has filed a ... Leukemia and other cancers .", "label": "", "metadata": {}, "score": "78.09131"}
{"text": "Tranexamic acid should be routinely used in trauma patients with evidence of bleeding ; .Tranexamic acid should be included in transfusion protocols for trauma ; .", "label": "", "metadata": {}, "score": "78.13382"}
{"text": "Closure strategies were utilized as necessary .Figure 1 : Access sites used in subjects undergoing TAVI from November 2007 to February 2012 .The devices used in this study were the Edwards - SAPIEN / SAPIEN XT ( ESV ) ( Edwards Lifesciences , Irvine , California ) and the Medtronic CoreValve ReValving Technology ( MCV ) ( Medtronic Inc. , Minneapolis , Minnesota ) .", "label": "", "metadata": {}, "score": "78.29508"}
{"text": "Active uncontrolled infection ( defined as exhibiting ongoing signs / symptoms related to the infection and without improvement , despite appropriate antibiotics or other treatment ) .", "label": "", "metadata": {}, "score": "78.74735"}
{"text": "Eliquis is approved for the prophylaxis of VTE in adult patients who have undergone elective hip or knee replacement surgery in the United States , European Union and a number of other countries around the world .", "label": "", "metadata": {}, "score": "78.80361"}
{"text": "To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .For general information , see Learn About Clinical Studies .", "label": "", "metadata": {}, "score": "79.11117"}
{"text": "The current recommendation to perform TAVI under a combination of heparin , aspirin , and clopidogrel is merely empiric and further studies are needed to identify the ideal choice of antiplatelet agent .", "label": "", "metadata": {}, "score": "79.18588"}
{"text": "All data were analysed using SPSS version 21.0 for Windows .Results are presented as mean \u00b1 standard deviation ( SD ) or median ( interquartile range ( IQR ) .", "label": "", "metadata": {}, "score": "79.26509"}
{"text": "Primary Feasibility Endpoint : Procedural failure , defined as inability to complete the procedure from the assigned vascular access site .[ Time Frame : From first arterial access post - randomization to 72 hours or hospital discharge , whichever occurs first . ]", "label": "", "metadata": {}, "score": "79.499886"}
{"text": "The antifibrinolytic drug tranexamic acid ( TXA ) , a lysine analogue , interferes with the binding of plasminogen to fibrin , which is necessary for plasmin activation .", "label": "", "metadata": {}, "score": "80.77765"}
{"text": "ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled .", "label": "", "metadata": {}, "score": "81.88575"}
{"text": "TBE - CITE CONCLUSION .The conclusions reached by at the telemedicine meeting are based on 3 recent publication and a systematic review : . \u00b7", "label": "", "metadata": {}, "score": "82.2783"}
{"text": "Other than as required by applicable law , sanofi - aventis does not undertake any obligation to update or revise any forward - looking information or statements .", "label": "", "metadata": {}, "score": "82.31883"}
{"text": "Jakafi is also the first JAK1/JAK2 inhibitor to demonstrate efficacy in a Phase III trial in patients with PV and will be the first JAK1/JAK2 inhibitor made available to patients with PV in the U.S. .", "label": "", "metadata": {}, "score": "82.32013"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01406236 Gastric Ulcers .February 18 , 2013 .", "label": "", "metadata": {}, "score": "82.35513"}
{"text": "Transcatheter aortic valve implantation ( TAVI ) has emerged as a valid treatment option for patients with symptomatic severe aortic stenosis and at high risk for conventional surgical aortic valve replacement .", "label": "", "metadata": {}, "score": "82.39853"}
{"text": "About DVT and PE .Venous thromboembolism , or VTE , encompasses two serious conditions : deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ) .", "label": "", "metadata": {}, "score": "82.50072"}
{"text": "Led by a team of experts with exceptional experience in developing new therapies for lipid disorders , Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease .", "label": "", "metadata": {}, "score": "82.770935"}
{"text": "Like clopidogrel , prasugrel is a pro - drug that requires metabolic activation .However , esterases that are known to inactivate clopidogrel act on prasugrel to prime it for activation by a single CYP - dependant oxidation step .", "label": "", "metadata": {}, "score": "82.79284"}
{"text": "The most common and most serious adverse reactions reported with ELIQUIS ( apixaban ) were related to bleeding .TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS .", "label": "", "metadata": {}, "score": "83.83649"}
{"text": "February 11 , 2016 , ...From March 4 through ...Dermatology Annual Meeting at the Walter E. Washington Convention Center in Washington , D.C. ... the condition of hyperhidrosis ( excessive sweating ) and its treatment options .", "label": "", "metadata": {}, "score": "83.963394"}
{"text": "The use of LOVENOX(R ) has not been adequately studied for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves .( See WARNINGS ) .", "label": "", "metadata": {}, "score": "84.261986"}
{"text": "Eliquis ( apixaban ) is an oral selective Factor Xa inhibitor .By inhibiting Factor Xa , a key blood clotting protein , Eliquis decreases thrombin generation and blood clot formation .", "label": "", "metadata": {}, "score": "84.63397"}
{"text": "LOVENOX(R ) ( enoxaparin sodium injection ) can not be used interchangeably with other low - molecular - weight heparins or unfractionated heparin , as they differ in their manufacturing process , molecular weight distribution , anti - Xa and anti - IIa activities , units , and dosage .", "label": "", "metadata": {}, "score": "85.04516"}
{"text": "Enoxaparin is an anticoagulant of the low molecular w eight heparin ( LMWH ) class .Its clinical applications are linked to its antithrombotic properties .", "label": "", "metadata": {}, "score": "85.41466"}
{"text": "February 11 , 2016 , ...As part of their 2015 end of ...Round Table Foundation ( MDRTF ) , has gifted $ 10,000 to University of Chicago to support ovarian ...", "label": "", "metadata": {}, "score": "85.96396"}
{"text": "Such forward - looking statements are based on current expectations and involve inherent risks and uncertainties , including factors that could delay , divert or change any of them , and could cause actual outcomes and results to differ materially from current expectations .", "label": "", "metadata": {}, "score": "86.20044"}
{"text": "Do not contact the Lupus Research Institute for information on these studies .Only contact the listed numbers .The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies , other than to make people aware that they are being conducted .", "label": "", "metadata": {}, "score": "87.007"}
{"text": "A specific antidote for ELIQUIS is not available .Hemodialysis does not appear to have a substantial impact on apixaban exposure .Protamine sulfate and vitamin K would not be expected to affect the anticoagulant activity of apixaban .", "label": "", "metadata": {}, "score": "87.29418"}
{"text": "Sanofi - aventis is listed in Paris and in New York .Forward Looking Statements .This press release contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended .", "label": "", "metadata": {}, "score": "87.29547"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "88.70203"}
{"text": "The study cohort is heavily made by a few countries ; 75 % originated in 6 nations ( India 4768 , Colombia 2940 , Egypt 2234 , Nigeria 2053 , Georgia 1783 , Ecuador 1198 ) .", "label": "", "metadata": {}, "score": "88.94223"}
{"text": "Thrombocytopenia can occur with LOVENOX(R ) .In patients with a history of heparin - induced thrombocytopenia , LOVENOX(R ) should be used with extreme caution .", "label": "", "metadata": {}, "score": "89.57477"}
{"text": "Prosthetic Heart Valves : The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients .", "label": "", "metadata": {}, "score": "91.1048"}
{"text": "At Pfizer , we apply science and our global resources to bring therapies to people that extend and significantly improve their lives .We strive to set the standard for quality , safety and value in the discovery , development and manufacture of health care products .", "label": "", "metadata": {}, "score": "91.42543"}
{"text": "Dateline : .Public Company Information : .The European Commission approval applies to all European Union ( EU ) member states as well as Iceland and Norway .", "label": "", "metadata": {}, "score": "92.04805"}
{"text": "12 , no .5 , pp .762 - 767 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "92.56322"}
{"text": "55 , no .11 , pp .1080 - 1090 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "94.34834"}
{"text": "Compartilhar .Rev. Col .Bras .Cir .vol.39 no.1 Rio de Janeiro 2012 .TBE - CITE .Luis da Luz I ; Ajith Sankarankutty II ; Edward Passos I ; Sandro Rizoli III ; Gustavo P. Fraga IV ; Bartolomeu Nascimento Jr V .", "label": "", "metadata": {}, "score": "94.87315"}
{"text": "32 , no . 2 , pp .191 - 197 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "95.56419"}
{"text": "Every day , Pfizer colleagues work across developed and emerging markets to advance wellness , prevention , treatments and cures that challenge the most feared diseases of our time .", "label": "", "metadata": {}, "score": "95.74872"}
{"text": "123 , no . 3 , pp .299 - 308 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "96.65926"}
{"text": "These statements include financial projections and estimates and their underlying assumptions , statements regarding plans , objectives , intentions and expectations with respect to future events , operations , products and services , and statements regarding future performance .", "label": "", "metadata": {}, "score": "98.10636"}
{"text": "( Date:2/11/2016 ) ... ...11 , 2016 , ...The book , \" Computers Should Just Work ! \" , provides a basic , ... your IT consultant before signing a contract and how to spot an incompetent or ... relying heavily on e - mail and technology , it 's more important than ever to make sure ... .", "label": "", "metadata": {}, "score": "102.42633"}
{"text": "PFIZER DISCLOSURE NOTICE : .The information contained in this release is as of July 29 , 2014 .Pfizer assumes no obligation to update forward - looking statements contained in this release as the result of new information or future events or developments .", "label": "", "metadata": {}, "score": "103.07472"}
{"text": "Epanova is a patent protected , novel , ultra - pure mixture of the free fatty acid forms of eicosapentaenoic acid ( EPA ) and docosahexaenoic acid ( DHA ) .", "label": "", "metadata": {}, "score": "106.07343"}
{"text": "[Links ] .Correspondence to : Bartolomeu Nascimento Jr. Address : Sunnybrook Health Sciences Centre 2075 Bayview Avenue , Room B5 12 Toronto , ON , Canada , M4N 3M5 .", "label": "", "metadata": {}, "score": "108.14815"}
{"text": "About the Bristol - Myers Squibb / Pfizer Collaboration .In 2007 , Pfizer and Bristol - Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban , an oral anticoagulant discovered by Bristol - Myers Squibb .", "label": "", "metadata": {}, "score": "108.24113"}
{"text": "The congress will ...PV is a myeloproliferative neoplasm ( MPN ) characterized by an overproduction of normal red blood cells , white blood cells and platelets that leads to an increased risk of thrombosis .", "label": "", "metadata": {}, "score": "108.55668"}
{"text": "Please see accompanying full prescribing information including boxed WARNING .About sanofi - aventis .Sanofi - aventis is one of the world 's leading pharmaceutical companies .", "label": "", "metadata": {}, "score": "110.73544"}
{"text": "For more than 150 years , Pfizer has worked to make a difference for all who rely on us .Bristol - Myers Squibb Forward - Looking Statement .", "label": "", "metadata": {}, "score": "114.07649"}
{"text": "About Bristol - Myers Squibb .Bristol - Myers Squibb is a global biopharmaceutical company whose mission is to discover , develop and deliver innovative medicines that help patients prevail over serious diseases .", "label": "", "metadata": {}, "score": "120.44001"}
{"text": "Received 27 August 2013 ; Accepted 13 November 2013 .Copyright \u00a9 2013 Caroline J. Magri et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "123.683395"}
